Company: JUNS
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001641172-25-001261
Chunk: 1044

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 3
Chunk 1044
---

    and defending intellectual property-related claims;

    ●
    our
    ability to establish and maintain collaborations on favorable terms, if at all;

    ●
    our
    efforts to enhance operational systems and our ability to attract, hire and retain qualified personnel, including personnel to support
    the development of our drug candidate;

    ●
    the
    costs associated with being a public company; and

    ●
    the
    cost associated with commercializing our drug candidate, if it receives marketing approval.

85

If
we raise additional funds by issuing equity securities, our stockholders may experience dilution. Any future debt financing into which
we enter may impose upon us additional covenants that restrict our operations, including limitations on our ability to incur liens or
additional debt, pay dividends, repurchase our common stock, make certain investments and engage in certain merger, consolidation or
asset sale transactions. Any debt financing or additional equity that we raise may contain terms that are not favorable to us or our
stockholders. If we are unable to raise additional funds when needed, we may be required to delay, reduce, or terminate some or all of
our development programs and clinical trials. We may also be required to sell or license to other parties rights to develop or commercialize
our drug candidate that we would prefer to retain.

See
“Risk Factors” for additional risks associated with our capital requirements.

Cash
Flows for the Years Ended December 31, 2024 and 2023

The
following table shows a summary of our cash flows for the years ended December 31, 2024 and 2023.

    Fiscal Years Ended December 31, 

    2024  
    2023 
  
    Net cash used in operating activities 
    $(3,911,004) 
    $(480,953)
  
    Net cash used in investing activities 
     -  
     - 
  
    Net cash provided by financing activities 
    $7,652,036  
    $445,000 
  
    Net increase (decrease) in cash 
    $3,741,032  
    $(35,953)
  
    Cash - beginning of the period 
    $   
    $  
  
    Cash - end of the period 
    $3,769,510  
    $28,478 

Net
Cash Used in Operating Activities:

Net
cash used in operating activities during the year ended December